about
Predictors of Ventricular Arrhythmias and Sudden Death in a Québec Cohort With Brugada Syndrome.Very Low Ventricular Pacing Rates Can Be Achieved Safely in a Heterogeneous Pacemaker Population and Provide Clinical Benefits: The CANadian Multi-Centre Randomised Study-Spontaneous AtrioVEntricular Conduction pReservation (CAN-SAVE R) Trial.Effect Of Catheter Ablation On Quality Of Life In Atrial Fibrillation.Atrial fibrillation in heart failure: drug therapies for rate and rhythm control.Cardiac Abnormalities in First-Degree Relatives of Unexplained Cardiac Arrest Victims: A Report From the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry.Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation: Insights From the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination) Trial.Outcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registry.Risk stratification for sudden death in arrhythmogenic right ventricular cardiomyopathy.Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application.The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients.Loss-of-Function KCNE2 Variants: True Monogenic Culprits of Long-QT Syndrome or Proarrhythmic Variants Requiring Secondary Provocation?Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Ne2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AF-CHF Substudy.ECG Features Associated With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation: A Combined AFFIRM and AF-CHF Analysis.Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines.Heart rate and adverse outcomes in patients with atrial fibrillation: A combined AFFIRM and AF-CHF substudy.Blood Pressure and Atrial Fibrillation: A Combined AF-CHF and AFFIRM Analysis.Systolic blood pressure and mortality in patients with atrial fibrillation and heart failure: insights from the AFFIRM and AF-CHF studies.Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead.Histopathology of cryoballoon ablation-induced phrenic nerve injury.Reply: To PMID 23265334.Pulmonary vein isolation using a second-generation cryoballoon catheter: a randomized comparison of ablation duration and method of deflation.Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction.Design of an acute dP/dt hemodynamic measurement protocol to isolate cardiac effect of pacing.Reducing radiation exposure during procedures performed in the electrophysiology laboratory.Focal Transcatheter Cryoablation: Is a Four-Minute Application Still Required?Reducing Radiation Exposure During CRT Implant Procedures: Single-Center Experience with Low-Dose Fluoroscopy Settings and a Sensor-based Navigation System (MediGuide).A look into the future of cardiology: perspectives from the Montreal Heart Institute.Impact of a Novel Catheter Tracking System on Radiation Exposure during the Procedural Phases of Atrial Fibrillation and Flutter Ablation.Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.Characterization of a Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for the Study of Variant Pathogenicity: Validation of a KCNJ2 Mutation.Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation.Nonsense mutations in BAG3 are associated with early-onset dilated cardiomyopathy in French Canadians.Electrocardiographic and electrophysiological predictors of atrioventricular block after transcatheter aortic valve replacement.Reducing radiation exposure during CRT implant procedures: early experience with a sensor-based navigation system.Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER).Response to Letter Regarding Article, "Outcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registry".
P50
Q33167377-73AE3E0E-271A-4C20-99DF-98C1CF47EB2DQ36168787-CABDABDC-022C-4234-AB18-F0F5ABB7D42CQ37469080-8AEB5280-8028-44AE-89A2-8A850CA11A6FQ38108265-4F709BD8-CE4C-4986-9E06-5E2E013918FEQ38387461-C2A3B971-4F50-4F76-AB34-E473C5E301CCQ38388955-F0AA1AB5-120B-4252-9908-050F804F65A0Q38397020-C42A7A16-1712-40EF-9924-943836249D16Q38462951-106A20D9-27B2-46B1-B4F4-CCC347FA924FQ38494265-3091FFA5-D772-4816-8D19-3811F87E6B31Q38610066-811FC865-2D7C-4064-98EE-D540EC887846Q38631722-1790B83A-D662-4FED-97FA-5E75E4FA418FQ38699658-F63C6779-F63C-480D-836E-77EBFF72AC7DQ38949789-4686E088-61DC-4566-A6CF-B9D6EDD4069FQ39195789-BB2ABCCE-73AB-4BAB-9B37-7A8642053408Q39853724-B662729F-A6B5-4A8A-8BA3-E405D2FDEBB1Q40391209-E180CAC4-5A65-4D70-8AAF-E81FE0D4AEB9Q40615353-043A261C-BC09-48D7-A7B1-44EEBA5CC2DEQ41332447-E77BCA3D-F478-418C-8CEE-59B6EB5E970FQ44003578-E47C6905-A6EF-434B-8E3A-D963630FB90CQ44015848-C1B74FEA-6FDB-4776-A013-87ABE5E3D89FQ44390821-AC45C4CB-4B1C-4FB8-B428-1B91DD17DB27Q44469072-5AE45B2C-45E6-45BA-BD5B-3EB71989946DQ45105382-A3F3B056-F22A-4EDC-857C-3B621160BBA1Q46004347-F8713CA9-2AED-4EB0-A92A-4CACB3221F56Q46073070-84BBA750-0198-42B7-8A21-1BCB2D039A5BQ47235681-CEC1C309-F575-4FE4-9AB4-44B2A71B7060Q47326524-2CA8D3E7-8C6C-4FAD-977F-91F7CE865924Q48604524-7090A81F-92DE-46D0-9A11-DDAD6F6DA7ACQ48659496-B1E7F243-7ABD-45A8-AF6E-C95E265AC45EQ48684118-788A2705-AFE6-44A7-A85E-87BDF068192EQ48973954-14B785E5-8552-424D-80F6-F72BF2599D47Q50095816-F6B85EAD-FA38-4063-8EC8-B90C89D5D81FQ50207106-47F9053B-5FC1-4013-BB6D-2DE02D178BD0Q50606987-FC6680D8-F1FC-428F-A0BD-B66F45C0213EQ50607109-E784C258-08E7-479B-BFA1-C6A0522B3CC9Q50607220-D4662D23-BFCD-4907-B541-0257BA648F43Q50952580-D2DCE760-2AA1-4AB3-91DB-39CA13E29A07Q51058191-8DB3D6A9-C394-4BEC-90C3-3D149A231F03Q51152085-B588FF94-700F-48CB-B661-1888893F04A3Q51375315-2F835BF6-89A1-467E-A5DA-0DC9E58A4D8D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mario Talajic
@en
Mario Talajic
@nl
type
label
Mario Talajic
@en
Mario Talajic
@nl
prefLabel
Mario Talajic
@en
Mario Talajic
@nl
P31
P496
0000-0001-8469-4748